medigraphic.com
ISSN 2448-8909 (Print)

2002, Number 4

Next >>

Med Crit 2002; 16 (4)

Epidemiology of acute myocardial infarction in the intensive

Manzo PE, Castro EMA

Language: Spanish
References: 58
Page: 113-118
PDF size: 73.59 Kb.


ABSTRACT

Introduction: The incidence of acute myocardial infarction (AMI) varies according the type of hospital of intensive care unit. Objective: To know the epidemiology of AMI in a polyvalent intensive care unit (ICU). Design: Retrospective and descriptive study. Setting: Polyvalent UCI of a general hospital, Mexico City. Patients: The files of sixty-six patients (55 men, 11 women, mean age 60.07 ± 11.09 yrs) with AMI were analyzed. Interventions: None. Measurements and main results: The main risk factors related with AMI were smoke 72.72%, systemic arterial hypertension 40.9%, dyslipidemias 28.78% and diabetes mellitus 25.75%. AMI was classified as anteroseptal (43.93%), inferior (39.39%), lateral (9.09%) and anterior 7.57%. The most frequent complications were premature ventricular contraction 27.27%, sinus bradycardia 18.18%, ventricular fibrillation 12.12% and third degree A-V block 12.12%. Conclusion: We found a major incidence of AMI in our unit in comparison to other polyvalent ICUS.


REFERENCES

  1. Castelli WP et al. Epidemiology of coronary heart disease: the Framingham Study. Am J Med 1984;76:4-12.

  2. Wilson PWF. Established risk factors and coronary artery disease. The Framingham Study. Am J Hypertens 1994;7: 7S-12S.

  3. Stampfer MJ, Hennekens CH, Manson JE et al. Vitamin E consumption and risk of coronary heart disease in women. N Engl J Med 1993;238:1444-1449.

  4. Beaglehole R. International trends in coronary heart disease, mortality, morbidity, and risk factors. Epidemiol Rev 1990;12:1-15.

  5. Bakker AJ, Koelemary MJ, Gorgels JP et al. Troponin T and mioglobin at admission: Value of early diagnosis of acute myocardial infarction. Eur Heart J 1994;15:45-53.

  6. Criqui MH et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-86.

  7. Cashin-Hemphill L et al. Beneficial effects of colestipolniacin on coronary atherosclerosis: A 4-years follow-up. JAMA 1990;264:3013-3017.

  8. Furberg CD, Byingron RP, Crouse JR et al. Pravastatin, lipids and major coronary events. Am J Cardiol 1993;72: 1031-1037.

  9. Gaspoz JM, Lee TH, Cook et al. Outcome of patients who were admitted to a new short-stay unit to “rule-out” myocardial infarction. Am J Cardiol 1991;68:145-149.

  10. Hearme SE et al. Adjunctive agents to reduce ischemia, preserve myocardial function and reduce mortality: Acute Coronary Care, Mosby Year Book 1995;p.p.335-369.

  11. He J et al. Mortality and apnea index in obstructive sleep apnea: Experience in 385 male patients. Chest 1988;94: 9-14.

  12. Gordon T et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1997;62:707-714.

  13. Kannel WB, D’ Agostino RB. Risk reduction after quitting smoking. Quality of life and cardiovascular Care 1989; 1:84-85.

  14. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: A randomized factorial trial assessing early or oral mononitrate, and intravenous magnesium sulphate in 58, 50 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.

  15. Williams MI et al. Acute myocardial infarction. A guide for North Carolina doctors: NC Med J 1995;56(8):390-397.

  16. Meldenson MA et al. Myocardial infarction in women. Cardiology 1995;86(4):272-85.

  17. Multiple risk factor intervention research group: Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA 1982;248:1465-1477.

  18. Brensike JF et al. Effects of therapy with colestiramine on progression of coronary arteriosclerosis: Results of the NHLBI type II coronary intervention study. Circulation 1984;69:313-324.

  19. Coronary drug project research group: Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.

  20. Fuster V, Badimon L, Dyken ML, Vokonas PS et al. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993;87:659-675.

  21. Leon AS, Connett J. For the MRFIT Research Group: Physical activity and 10.5 year mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Int Epidemiol 1991;20:690-697.

  22. Kane JP, Malloy MI, Ports TA et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007-3012.

  23. Lott KJA et al. Time changes of creatine kinase and creatine kinase MB isoenzyme versus discrimination values in the diagnosis of acute myocardial infarction: What is the optimal method fosdisplayimg the date? Eur J Clin Chem Clin Biochem 1995;33(8):491-8.

  24. MacMahom S et al. Blood pressure, stroke and coronary heart disease in older persons and women. Lancet 1990;335:765-774.

  25. Muller JE et al. Circadian variation and cardiovascular disease. N Engl J Med 1991;325:1038-1039.

  26. Krumholz HM et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly; prescribed used and outcomes. Ann Inter Med 1996;1(2):292-8.

  27. Goldman L et al. A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med 1988;318:797803.

  28. Grover A et al. The importance of early patency after acute myocardial infarction. Curr Opin Cardiol 1995;11(4): 361-366.

  29. Arntzenius AC et al. Diet, Lipoproteins, and the progression of coronary atherosclerosis: The leiden Intervention Trial. N Engl J Med 1985;312:805-11.

  30. Bosh X, Therous P, Waters DD et al. Early post-infarction ischemia: Clinical angiographic and prognostic significance. Circulation 1997;75:988-995.

  31. Austin MA et al, Plasma triglyceride and coronary heart disease. Arterioescler Thromb 1991:2-14.

  32. Brenkenhorn DH, Azen SP, Kramsh DM et al. Coronary angiographic changes in lovastatin therapy: The monitored atherosclerosis regression study (MARS). Ann Intern Med 1993;119:969-976.

  33. Hill MF et al. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Patol 1996;148(1):291-300.

  34. Grundy SM et al. The place of HDL in cholesterol management: A perspective from the national cholesterol education programs. Arch Intern Med 1989;149:505-510.

  35. Lipid Research Clinics Program: The Lipids Research Clinics Coronary Primary Prevention Trial Results. 11. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.

  36. Muscari et al. Serum C3 as a screening factor in the primary prevention of myocardial infarct. Cardiologia 1995; 40(7):507-14.

  37. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results. l. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.

  38. Pitt B. Reduction in cardiovascular events during treatment with pravastatin: Pooled analysis from coronary and carotid atherosclerosis. Eur Heart J 1994;15:487.

  39. Nodek et al. Increased release of NO during ischemia reduces myocardial contractile and improves metabolic dysfunction. Circulation 1996;93(2):35664.

  40. GISSI-3: Effects lisinopril and transdermal glyceryl trinitrate after acute myocardial infarction. Lancet 1994;343: 1115-1122.

  41. GISSI-2: Six-Month survival in 20,981 patients with acute myocardial infarction randomized between alteplase and streptokinase with acute myocardial infarction randomized International Study Group. Eur Heart J 1992;13:1692-97.

  42. Gill JB et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med 1996;334(2):65-70.

  43. Adachi TJ et al. Effect of verapamil on myocardial stunning in xantine oxidase deficit heart pre-treatment vs post ischemic treatment. Basic Res Cardiol 1994;89(1):16-28.

  44. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.

  45. Jeunemaitre X, Soubrier F, Kotelertsev YV et al. Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992;71:169-180.

  46. Hollander JE et al. The management of cocaine-associated myocardial ischemia. N Engl J Med 1995;333(19):1267-72.

  47. Kannel WB, Wolf R, Castelli WP et al. Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987;258:1183-1186.

  48. Kasel AM et al. B2 bradykinin receptor in cultured neonatal rat cardiomyocytes mediate a negative chronotropic and negative inotropic response. Diabetes 1996;45 suppl 1:544-50.

  49. Keys A. Coronary heart disease in seven countries (American Heart Association Monograph 29). Circulation 1970; 41(suppl 1):1-211.

  50. Zavaroni Y, Bonora E, Pagliara M et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucosa tolerance. N Engl J Med 1989;320:702-706.

  51. Weinberger MH. Antihypertensive therapy and lipids: Evidence mechanisms and implications. Arch Inter Med 1985;145:1102-1105.

  52. Roussean M, Lewis B, Rifkin BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;32:1112-1119.

  53. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.

  54. Gawaz M et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93(2):229-37.

  55. Fibrinolytic Therapy trialists’ collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction. Lancet 1994;343:311-22.

  56. Coulson CC et al. Myocardial infarction and coronary artery dissection in pregnancy. Am J Perinatol 1995;12(5): 328-330.

  57. ISSIS-1 (First International Study of Infarct Survival) Collaborative Group: Randomized Trial of Intravenous Atenolol among 16,027 cases of suspected myocardial infarction: ISIS -1. Lancet 1986;57-66.

  58. ISIS-2 Randomized trial of intravenous streptokinase, oral aspirin both, or neither among: ISIS 2. Lancet 1988;2: 340-360.




2020     |     www.medigraphic.com